Department of Hematology, Clinical Hospital Center Zemun, Vukova 9, 11080, Belgrade, Serbia.
Med Oncol. 2013 Dec;30(4):741. doi: 10.1007/s12032-013-0741-2. Epub 2013 Oct 2.
Our recent data have linked plasma phospholipid fatty acid (FA) profile in patients with non-Hodgkin's lymphoma (NHL) with the clinical stage and aggressiveness of the disease. Thus, we proposed that plasma FA status in these patients may influence the effect of chemotherapy. The aim of this work was to assess FA status in NHL patients undergoing chemotherapy in relation to their response to therapy. We analyzed plasma FA profile in 47 newly diagnosed NHL patients before chemotherapy, after 3 cycles and after the end of the planned chemotherapy. Patients were treated according to the hospital protocol: 28 patients with cyclophosphamide, doxorubicin, vincristine and prednisone, 7 with other anthracycline-containing regimens, 4 patients with cyclophosphamide, vincristine and prednisone and 8 with fludarabine-based regimens. Rituximab was added in 22 patients. Ten patients who did not receive all planned chemotherapy due to death or toxicity (non-completers) had significantly lower (p < 0.05) baseline proportion of palmitoleic, linoleic, eicosapentaenoic and docosahexaenoic acid, as well as n-3 and n-6 FA, than the patients who completed chemotherapy (completers). Furthermore, the completers were divided according to the response to chemotherapy to complete remission (CR), stable disease and progressive disease (PD). Proportion of palmitic acid after the end of chemotherapy was the highest in the PD group, while stearic acid showed the opposite trend. Palmitoleic acid and all n-3 FA (18:3, 20:5, 22:5 and 22:6) were the highest in the patients in remission and the lowest in PD (p < 0.001). Linoleic acid decreased and arachidonic acid increased from the CR to the PD group (p < 0.001). These results suggest that aberrations in plasma FA may influence response to chemotherapy in patients with NHL.
我们最近的数据将非霍奇金淋巴瘤（NHL）患者的血浆磷脂脂肪酸（FA）谱与疾病的临床分期和侵袭性联系起来。因此，我们提出这些患者的血浆 FA 状况可能影响化疗的效果。本工作旨在评估正在接受化疗的 NHL 患者的 FA 状况与其对治疗的反应之间的关系。我们分析了 47 例新诊断的 NHL 患者在化疗前、化疗 3 个周期后和计划化疗结束后的 FA 谱。患者根据医院方案进行治疗：28 例接受环磷酰胺、多柔比星、长春新碱和泼尼松，7 例接受其他含蒽环类药物的方案，4 例接受环磷酰胺、长春新碱和泼尼松，8 例接受氟达拉滨为基础的方案。22 例患者加用利妥昔单抗。由于死亡或毒性（未完成者）而未接受所有计划化疗的 10 例患者的基线棕榈油酸、亚油酸、二十碳五烯酸和二十二碳六烯酸以及 n-3 和 n-6 FA 的比例明显较低（p<0.05），比完成化疗的患者（完成者）。此外，根据对化疗的反应将完成者分为完全缓解（CR）、稳定疾病和进展性疾病（PD）。化疗结束后棕榈酸的比例在 PD 组中最高，而硬脂酸则呈现相反的趋势。棕榈油酸和所有 n-3 FA（18:3、20:5、22:5 和 22:6）在缓解患者中最高，在 PD 中最低（p<0.001）。亚油酸从 CR 组到 PD 组减少，花生四烯酸增加（p<0.001）。这些结果表明，血浆 FA 的异常可能影响 NHL 患者对化疗的反应。
